Inflammation

Feinstein Institutes bioelectronic medicine researchers stimulate vagus nerve to reduce bleeding in hemophilia

Retrieved on: 
Thursday, June 1, 2023
Health, Neurology, Other Health, Clinical Trials, Research, Science, Biotechnology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Elmezzi Graduate School of Molecular Medicine, Communication, Medicine, Donald, Travel, Bleeding, Education, Diabetes, Inflammatory Bowel Diseases, Feinstein Institutes for Medical Research, Vagus nerve, Arthritis, Nature Communications, Cancer, Haemophilia, DRS, Vagus nerve stimulation, Multimedia, Brain, Inflammation, Northwell Health, Crohn's disease, Spleen, MD, Patient, Blood, Mouse, Coagulopathy, Paper, Bacteria, Heart rate, Haemophilia A, Pulmonary hypertension, Death, Virus, Medical research, Disease, Birth control, Dentistry

Researchers at The Feinstein Institutes for Medical Research have shown that electrically stimulating the vagus nerve can reduce bleeding in preclinical hemophilic mice models – a finding that could translate into human patients.

Key Points: 
  • Researchers at The Feinstein Institutes for Medical Research have shown that electrically stimulating the vagus nerve can reduce bleeding in preclinical hemophilic mice models – a finding that could translate into human patients.
  • The study, published in Nature Communications , builds on years of research into harnessing the vagus nerve through electrical stimulation, a foundation of bioelectronic medicine.
  • (Feinstein Institutes)
    Led by Jared Huston, MD , associate professor of surgery and science education at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Institute of Bioelectronic Medicine at the Feinstein Institutes, the research shows that vagus nerve stimulation reduces bleeding in hemophilia A mice to the same degree as replacing missing clotting factor – the current gold-standard therapy for patients living with hemophilia.
  • Huston’s new findings indicate it may be possible to stop life-threatening bleeding by stimulating the vagus nerve.”
    The Feinstein Institutes is known as the global scientific home of bioelectronic medicine because of early discoveries in its labs.

Inotrem Announces Publication of Two Key Articles on Nangibotide Phase II Programs in Peer-reviewed Medical Journals

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Medical Devices, Research, Infectious Diseases, Science, COVID-19, Clinical Trials, SOFA, Infection, The Lancet, Inflammation, Septic shock, Patient, Manuscript, Mortality, Respiratory failure, Safety, COVID19, Disease, Pharmaceutical industry

The first article presents the ASTONISH Phase 2b trial in septic shock patients and the second one the ESSENTIAL Phase 2 trial for the treatment of critically ill COVID-19 patients.

Key Points: 
  • The first article presents the ASTONISH Phase 2b trial in septic shock patients and the second one the ESSENTIAL Phase 2 trial for the treatment of critically ill COVID-19 patients.
  • The findings presented further validate Inotrem’s innovative approach to treat inflammatory diseases by targeting TREM-1.
  • “Nangibotide is the first TREM-1 inhibitor and has the potential to become the first causal treatment of life-threatening immune dysregulations.
  • “We look forward to bringing this potential new treatment option to patients suffering from severe and often fatal inflammatory conditions.”

CAMH study confirms ongoing brain inflammation associated with long COVID

Retrieved on: 
Thursday, June 1, 2023
Inflammation, Depression, Anxiety, CAMH, COVID-19, Hope, PET, Brain, Research, COVID, Amnesia, Parkinson's disease, Patient, TSPO, Psychiatry, Motivation, JAMA Psychiatry, Encephalitis, Memory, Fatigue, Pharmaceutical industry, Medical imaging, Medical device

TORONTO, June 1, 2023 /CNW/ - A new CAMH study published in the journal JAMA Psychiatry found elevated levels of inflammation in the brain of patients who report persistent symptoms of long COVID.

Key Points: 
  • TORONTO, June 1, 2023 /CNW/ - A new CAMH study published in the journal JAMA Psychiatry found elevated levels of inflammation in the brain of patients who report persistent symptoms of long COVID.
  • "We already knew that there is brain inflammation in people who died in the midst of a severe, active COVID-19 infection.
  • "Inflammation in the brain was suspected of being the critical step in causing neurological and psychiatric symptoms of long COVID so confirming this is vital to develop treatments for people experiencing symptoms."
  • Most participants also experienced a variety of other lingering symptoms associated with long COVID, including extreme fatigue and problems with concentration and memory often referred to as 'brain fog'.

Allergy & Asthma Network Launches New Education Campaign: 'Is Your Asthma Under Control'

Retrieved on: 
Wednesday, May 31, 2023
Well, Asthma, Network, Education, Life, Nursing, Smartphone, Credible messenger program, Quality of life, Allergy, Inflammation, Cell, Better, Eosinophil, CDC, Death, Walking, Patient, Blood, Control, Research, Mitchell, USA Today, Mucus, Conditional sentence, Disease, Pharmaceutical industry

Allergy & Asthma Network is launching a year-long awareness campaign on the importance of asthma control to improve respiratory health and quality of life.

Key Points: 
  • Allergy & Asthma Network is launching a year-long awareness campaign on the importance of asthma control to improve respiratory health and quality of life.
  • Allergy & Asthma Network has developed a series of web-based resources to better educate patients about asthma control and treatments:
    EosAsthma.org – Eosinophilic asthma is a subtype of asthma that is often severe.
  • Allergy & Asthma Network offers free asthma coaching through its Not One More Life Trusted Messengers Program.
  • Allergy & Asthma Network's asthma coaches are certified asthma educators with additional licenses as respiratory therapists, physician assistants and nursing.

I'm over 65 and worried about the flu. Which vaccine should I have?

Retrieved on: 
Thursday, June 1, 2023
Vaccine, Infection, Heart, Immunology, Australian Technical Advisory Group on Immunisation, Vaccination, Immunization, National Immunisation Program Schedule, Fever, Cancer, Therapeutic Goods Administration, Working group, Immunity, MF59, COVID, Inflammation, Antibody, Cough, Adaptive immune system, Death, Mask, Immunosenescence, Risk, Immune system, Viral, N95, Sneeze, Ageing, TGA, Headache, Meat, Influenza vaccine, H1N1

It can cause the sudden onset of a fever, cough, runny nose, sore throat, headache, muscle and joint pain.

Key Points: 
  • It can cause the sudden onset of a fever, cough, runny nose, sore throat, headache, muscle and joint pain.
  • In Australia, the flu is responsible for more than 5,000 hospitalisation and 100 deaths a year.
  • To combat the decline in immunity as we age, specific vaccines are available for people aged 65 and over.

Remind me, how does the immune system work?

    • The immune system uses multiple mechanisms to fight viral infections, which can be divided into two major arms of the immune system, called innate and adaptive immunity.
    • Innate immunity involves multiple inflammatory cells and chemicals that are triggered immediately, or within hours of encountering an infection.

Why are older people more at risk from the flu?

    • This immune system decline is called immunosenescence, which leads to increased susceptibility, hospitalisation and death from influenza.
    • Certain medical conditions, such as cancer and heart and lung conditions, increase susceptibility to severe influenza, with older people being more likely to have additional medical conditions than younger people.

What flu vaccines are available?

    • Annual flu vaccines are recommended to protect against the common circulating strains of influenza, which can differ from year to year.
    • The standard flu vaccines offered to adults aged under 65 consist of surface proteins of the virus or inactivated (killed) virus from four influenza strains: two A strains (H1N1 and H3N2) and two B strains.
    • Read more:
      Why can you still get influenza if you've had a flu shot?

How do they compare?

    • In the few studies comparing Fluad and Fluzone directly, there is little evidence of a difference between them in reducing influenza and serious flu outcomes.
    • Fluzone is only available with a private prescription if you’re 60 years and over, at a cost of around A$65-70.
    • If neither augmented vaccine is available, a standard influenza vaccine is also acceptable for older people, since any influenza vaccine is preferable to receiving none.

How else can we protect against the flu?

    • Wearing a mask or N95 respirator significantly reduces the risk of infecting others when infected.
    • The evidence for protecting oneself against infection is less conclusive, mainly because it’s linked to early, consistent and, importantly, the correct use of masks.
    • Read more:
      Over half of eligible aged care residents are yet to receive their COVID booster.

IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

Retrieved on: 
Wednesday, May 31, 2023
Inflammation, Tissue, Rituximab, RA, IGM, CRS, CD20, Drug discovery, Immunoglobulin M, NHL, Pharmacokinetics, Lead, Autoimmunity, SLE, Incidence, Cytokine release syndrome, Patient, Autoimmune disease, Immune system, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, IND, Food, Rheumatoid arthritis, Vaccine

The Company plans to begin patient enrollment in both multicenter clinical studies in the third quarter of 2023.

Key Points: 
  • The Company plans to begin patient enrollment in both multicenter clinical studies in the third quarter of 2023.
  • “Over the last two decades, CD20 has become well-established as a therapeutic target in multiple autoimmune diseases.
  • In preclinical in vivo studies, imvotamab has demonstrated deep B cell depletion within tissues, where depletion of pathogenic immune cells may be critical to long-term clinical benefit in autoimmune diseases.
  • Imvotamab has also demonstrated in preclinical in vitro studies that it can be more effective in depleting B cells with low levels of CD20 expression as compared to rituximab.

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 31, 2023
Inflammation, Pharmaceutical industry, Broadcasting

ENCINITAS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:

Key Points: 
  • ENCINITAS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
    A webcast of each event will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com .
  • A webcast replay will also be available on this website shortly after conclusion of the event for thirty days.

Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors

Retrieved on: 
Wednesday, May 31, 2023
Oncology, IPO, Partnership, Drug development, University, Therapy, Senior, Georgia Tech, Ear, Harvard University, AMD, Business, University of Pennsylvania, MBA, Nanomedicine, Inflammation, Cell, Messenger, Science, Regenerative medicine, MS, Wharton School of the University of Pennsylvania, Novartis, Patient, Verus Pharmaceuticals, Triple accreditation, Widener University Commonwealth Law School, Harvard Business School, ALS, Corporate development, Pharmaceutical industry, Ashvattha

“We are pleased to welcome Paul and Mahesh to Ashvattha,” said Jeff Cleland, Ph.D., CEO, co-founder, and Chairman of Ashvattha Therapeutics.

Key Points: 
  • “We are pleased to welcome Paul and Mahesh to Ashvattha,” said Jeff Cleland, Ph.D., CEO, co-founder, and Chairman of Ashvattha Therapeutics.
  • Prior to joining Ashvattha, Paul served as Chief Financial and Business Officer at Otonomy, a company that specialized in developing therapeutics for diseases and disorders of the ear.
  • Paul received his bachelor’s degree in biomechanical engineering from Harvard University and an MBA from the Harvard Business School.
  • Mahesh holds an MBA from the Wharton School, University of Pennsylvania, and an MS from Georgia Institute of Technology.

Analog Pharma and Dipharma announce US FDA approval of abbreviated new drug application (ANDA) of 20 mg generic Nitisinone capsules (temperature stable)

Retrieved on: 
Wednesday, May 31, 2023
Cornea, Tyrosine, Analog, Hair loss, Pharmacy, Skin, Scar, Immunity, Nitisinone, Temperature, Liver transplantation, Cataract, Inflammation, Cell, Rash, Phenylalanine, Capsule, Patient, ANDA, Cover My Eyes (Pain and Heaven), Rare, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

PRINCETON, N.J. and CHIASSO, Switzerland, May 31, 2023 (GLOBE NEWSWIRE) -- Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) are pleased to announce that their 20 mg nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug Administration.

Key Points: 
  • PRINCETON, N.J. and CHIASSO, Switzerland, May 31, 2023 (GLOBE NEWSWIRE) -- Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) are pleased to announce that their 20 mg nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug Administration.
  • Nitisinone Capsules are a room temperature stable, AB-rated, generic equivalent of Swedish Orphan Biovitrum's Orfadin®, and are now available in 2, 5, 10 and 20 mg capsules.
  • Analog currently distributes the 2, 5, and 10 mg products through specialty pharmacies and now has available the 20 mg capsules for distribution.
  • Tanya Carro, Executive Vice President, Analog Pharma, commented, “With the approval of the 20 mg capsule, we now have a full complement of room temperature stable strengths for our generic Nitisinone.

GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset

Retrieved on: 
Wednesday, May 31, 2023
Anoxic waters, US Foods, Heart failure, Hepatology, IQVIA, Inflammation, NTZ, LPS, SOC, Liver, Fibrosis, Kidney, ROS, Orphan drug, Investigational New Drug, Acquisition, Patient, Standard of care, Apoptosis, Ascites, ASK1, Multi, FDA, Therapy, IND, Safety, Pharmaceutical industry, Vaccine, Dietary supplement, ACLF, Euronext

ACLF is a complex disorder that will likely require the combination of different approaches and with this acquisition, we continue to strengthen our leadership in this indication.

Key Points: 
  • ACLF is a complex disorder that will likely require the combination of different approaches and with this acquisition, we continue to strengthen our leadership in this indication.
  • We now have a unique portfolio of three differentiated clinical stage programs in ACLF.
  • It is planned that approximately 60 adult patients with ACLF grades 1 and 2 will be enrolled in this trial.
  • Data expected to be available in the first half of 2024 should support preparation of further testing of efficacy.